<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03233230</url>
  </required_header>
  <id_info>
    <org_study_id>MS200527-0060</org_study_id>
    <secondary_id>2017-000384-32</secondary_id>
    <nct_id>NCT03233230</nct_id>
  </id_info>
  <brief_title>Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the efficacy, dose response, and safety of
      evobrutinib in subjects with Rheumatoid Arthritis (RA), and to consider a dose to take
      forward into Phase III development.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2017</start_date>
  <completion_date type="Actual">September 23, 2019</completion_date>
  <primary_completion_date type="Actual">September 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Achieving American College of Rheumatology 20% Response Criteria (ACR20) Assessed Using High-Sensitivity C-reactive Protein (hsCRP)</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With low Disease Activity Score (DAS28 &lt; 3.2) Based on 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP)</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Remission Disease Activity Score (DAS28 &lt; 2.6) Based on a 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP)</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving American College of Rheumatology 50% Response Criteria (ACR50) Assessed Using High-Sensitivity C-reactive Protein (hsCRP)</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving American College of Rheumatology 70% Response Criteria (ACR70) Assessed Using High-Sensitivity C-reactive Protein (hsCRP)</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Boolean Remission</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Clinical Disease Activity Index (CDAI) score =&lt; 2.8 (CDAI Remission)</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Simplified Disease Activity Index (SDAI) score =&lt;3.3 (SDAI remission)</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EULAR Responder Index (based on DAS-hsCRP)</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology (ACR) Hybrid Scores Computed Using High-Sensitivity C-reactive Protein(hsCRP)</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score Based on a 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline of Individual Components of the American College of Rheumatology (ACR) Core Set at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline of Individual Components of the ACR Core Set at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Synovitis Score According to the Outcomes Measures in Rheumatology Clinical Trials' Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (OMERACT RAMRIS) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bone Marrow Edema (Osteitis) Score According to the Outcomes Measures in Rheumatology Clinical Trials' Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (OMERACT RAMRIS) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Physical Function Using Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Health Related Quality of Life (HRQoL) Assessed by Medical Outcomes Study 36-item Short Form Health Survey (SF-36) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Health Related Quality of Life (HRQoL) Using Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treatment-emergent Adverse (TEAEs) and Serious TEAEs</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of TEAEs and Serious TEAEs by severity</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Clinically Significant Change From Baseline in Vital Signs, Laboratory Parameters and Electrocardiogram Findings</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values and Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM)</measure>
    <time_frame>Baseline and up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values and Change From Baseline in Total B cell Counts</measure>
    <time_frame>Baseline and up to 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">390</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Evobrutinib Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Evobrutinib Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Evobrutinib High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evobrutinib</intervention_name>
    <description>Evobrutinib low dose will be administered orally for 12 weeks.</description>
    <arm_group_label>Evobrutinib Low Dose</arm_group_label>
    <other_name>M2951</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evobrutinib</intervention_name>
    <description>Evobrutinib mid dose will be administered orally for 12 weeks.</description>
    <arm_group_label>Evobrutinib Mid Dose</arm_group_label>
    <other_name>M2951</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evobrutinib</intervention_name>
    <description>Evobrutinib high dose will be administered orally for 12 weeks.</description>
    <arm_group_label>Evobrutinib High Dose</arm_group_label>
    <other_name>M2951</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to evobrutinib will be administered orally for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Subjects will receive stable background therapy of methotrexate 7.5 to 25 mg/week (oral or parenteral) for &gt;= 16 weeks.</description>
    <arm_group_label>Evobrutinib High Dose</arm_group_label>
    <arm_group_label>Evobrutinib Low Dose</arm_group_label>
    <arm_group_label>Evobrutinib Mid Dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In Japan, if a subject is less than (&lt;) 20 years, the written informed consent from
             the subject's parent or guardian will be required in addition to the subject's written
             consent.

          -  Confirmed diagnosis of RA according to 2010 ACR/EULAR RA classification criteria of at
             least 6 months duration prior to Screening

          -  Persistently active moderate to severe RA at both Screening and Randomization (if
             significant surgical treatment of a joint has been performed, that joint cannot be
             counted for entry or enrollment purposes), as defined by: &gt;= 6 swollen joints (of 66
             assessed) and &gt;= 6 tender joints (of 68 assessed).

          -  An hsCRP &gt;= 5.0 milligram/liter (mg/L) at Screening

          -  Treatment for &gt;= 16 weeks with 7.5 to 25 mg/week Methotrexate (MTX) at a stable dose
             and route of administration (oral or parenteral) for at least 8 weeks prior to dosing
             with the Investigational Medicinal Product (IMP) and maintained throughout the trial

          -  For subjects entering the trial on MTX doses &lt; 15 mg/week (&lt; 10 mg/week in Japan),
             there must be clear documentation in the medical record that higher doses of MTX were
             not tolerated or that the dose of MTX is the highest acceptable dose based on local
             clinical practice guidelines.

          -  For MRI Sub-study subjects, subjects must have palpable synovitis of the wrist and/or
             &gt;= 1 of metacarpophalangeal joints 1 to 5, defined as loss of bony contours with
             palpable joint effusion and/or swelling, in the MRI-designated hand (that is., the
             hand being used in MRI assessments).

        Exclusion Criteria:

          -  ACR functional class IV as defined by the ACR classification of functional status or
             wheelchair/bedbound

          -  Use of oral corticosteroids greater than (&gt;) 10 mg daily prednisone equivalent, or
             change in dose of corticosteroids within 2 weeks prior to Screening or during
             Screening

          -  Use of injectable corticosteroids (including intra-articular corticosteroids) or
             intra-articular hyaluronic acid within 4 weeks prior to Screening or during Screening

          -  Initiation or change in dose for nonsteroidal anti-inflammatory drugs (NSAIDs)
             (including low-dose aspirin and cyclooxygenase-2 inhibitors) within 2 weeks prior to
             dosing with the IMP

          -  High potency opioid analgesics are prohibited within 2 weeks prior to Screening and
             during the trial; other analgesics are allowed (that is, acetaminophen, codeine,
             hydrocodone*, propoxyphene*, or tramadol), although not within 24 hours of study
             visits with clinical assessments (*not approved in Japan)

          -  Current or prior treatment with any of the following:

          -  Biologic Disease-modifying anti-rheumatic drugs (DMARDs) (approved or
             investigational), including but not limited to:

          -  Tumor necrosis factor (TNF) antagonists or biosimilars of these agents (approved or
             investigational), or any investigational TNF antagonist

          -  Interleukin-6 antagonists

          -  Abatacept (CTLA4-Fc)

          -  Anakinra* (IL-1 receptor antagonist) (*not approved in Japan)

          -  B cell-depleting antibodies (example, rituximab, ocrelizumab*, ofatumumab,
             obinutuzumab*, ocaratuzumab*, veltuzumab*, or any biosimilars of these agents
             [approved or investigational]) (*not approved in Japan)

          -  Anti-BLyS (B lymphocyte stimulator) agents (example, belimumab, tabalumab*) (*not
             approved in Japan)

          -  Dual BLyS/A proliferation-inducing ligand (APRIL) neutralizing agents (that is,
             atacicept*, RCT-18*) (*not approved in Japan)

          -  Targeted synthetic DMARDs, specifically:

          -  Janus kinase inhibitors

          -  Other Bruton's tyrosine kinase (BTK) inhibitors

          -  Alkylating agents (example, chlorambucil*, cyclophosphamide) (*not approved in Japan).

          -  The following restrictions on nonbiologic DMARD must be followed:

          -  Auranofin (Ridaura), minocycline, penicillamine, sulfasalazine, cyclosporine,
             mycophenolate (mycophenolate sodium not approved in Japan), tacrolimus, azathioprine:
             must have been discontinued for 4 weeks prior to dosing with the IMP

          -  Leflunomide (Arava) must have been discontinued 12 weeks prior to dosing with the IMP
             if no elimination procedure is followed. Alternately, it should have been discontinued
             with the following elimination procedure at least 4 weeks prior to dosing with the
             IMP:

          -  Cholestyramine at a dosage of 8 gram 3 times a day for at least 24 hours, or activated
             charcoal at a dosage of 50 gram 4 times a day for at least 24 hours.

          -  Injectable Gold (aurothioglucose* or aurothiomalate): must have been discontinued for
             8 weeks prior to dosing with the IMP (*not approved in Japan)

          -  Anti-malarials (hydroxychloroquine, chloroquine*) will be allowed in this trial.
             Subjects may be taking oral hydroxychloroquine (=&lt; 400 mg/day) or chloroquine (=&lt; 250
             mg/day), doses must have been stable for at least 12 weeks prior to dosing with the
             IMP, and will need to be continued at that stable dose for the duration of the trial.
             If discontinued prior to this trial, they must have been discontinued for 4 weeks
             prior to dosing with the IMP (*not approved in Japan).

          -  For MRI Substudy:

          -  Inability to comply with MRI scanning, including contraindications to MRI such as
             known allergy to gadolinium contrast media, claustrophobia (if the site does not have
             ability to scan extremities only), presence of a pacemaker, cochlear implants,
             ferromagnetic devices or clips, intracranial vascular clips, insulin pumps, and nerve
             stimulators.

          -  More than 25% of applicable joints of the target hand and wrist having had prior
             surgery or showing maximum Genant-modified Sharp erosion (3.0) or joint-space
             narrowing (4.0) scores, based on single posteroanterior radiographs of target hand and
             wrist read centrally.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono Research &amp; Development Institute, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Associates, P.C.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Research, PLLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Bay Rheumatology Medical Group, Inc.</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McIlwain Medical Group, PA</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medication Management, LLC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinic Of Central Texas</name>
      <address>
        <city>San Marcos</city>
        <state>Texas</state>
        <zip>78666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de La Plata</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>B1900AXI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600FZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico CER</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <zip>B1878DVB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas Quilmes</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <zip>B1878GEG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Privado de Reumatologia</name>
      <address>
        <city>Tucuman</city>
        <state>San Miguel De Tucuman</state>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Reumatológicas</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>T4000BRD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Organizacion Medica de Investigacion (OMI)</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APRILLUS</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1046AAQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Expertia S.A- Mautalen Salud e Investigación</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1128AAE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos Dr. J. M. Ramos Mejia</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ILAIM-CEOM Inst. Latinoamericano de Inv. Medicas</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000BNB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Reumatológico Strusberg</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000EDC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Polivalente de Asistencia e Inv. Clinica CER</name>
      <address>
        <city>San Juan</city>
        <zip>5400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Hadzhi Dimitar&quot;, OOD</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCC &quot;Alexandrovska&quot;, EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;SofiaMed&quot;, OOD</name>
      <address>
        <city>Sofia</city>
        <zip>1797</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Prosalud</name>
      <address>
        <city>Santiago</city>
        <zip>7500000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interin</name>
      <address>
        <city>Santiago</city>
        <zip>7500010</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioMedica Research Group</name>
      <address>
        <city>Santiago</city>
        <zip>7500710</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios Reumatologicos</name>
      <address>
        <city>Santiago</city>
        <zip>7501126</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Reumatologia y Ortopedia SAS</name>
      <address>
        <city>Barranquilla</city>
        <zip>080001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riesgo de Fractura S.A.</name>
      <address>
        <city>Bogota</city>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simedics Ips Sas</name>
      <address>
        <city>Bogotá</city>
        <zip>111211</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion en Reumatologia y Especialidades Medicas SAS. CIREEM</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servimed S.A.S.</name>
      <address>
        <city>Bucaramanga</city>
        <zip>680003</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Artritis Temprana S.A.</name>
      <address>
        <city>Cali</city>
        <zip>76001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatolog, s.r.o</name>
      <address>
        <city>Jihlava</city>
        <zip>586 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARTROSCAN s.r.o.</name>
      <address>
        <city>Ostrava - Trebovice</city>
        <zip>722 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Ostrava s.r.o.</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLINTRIAL s.r.o.</name>
      <address>
        <city>Praha 10</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice</name>
      <address>
        <city>Praha 4 - Krc</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDR. Zuzana URBANOVA Revmatologie</name>
      <address>
        <city>Praha 4 Nusle</city>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDR. Zuzana URBANOVA Revmatologie</name>
      <address>
        <city>Praha 4</city>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDICAL PLUS s.r.o.</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PV-MEDICAL s.r.o.</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Investigacion en Artritis y Osteoporosis S.C.</name>
      <address>
        <city>Mexicali</city>
        <state>Baja California Norte</state>
        <zip>21200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RM Pharma Specialists SA de CV</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Investigacion en Reumatologia y Obesidad S.C.</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigacion y Biomedicina de Chihuahua, S.C.</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion y Atencion Integral Durango CIAID</name>
      <address>
        <city>Durango</city>
        <zip>34270</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinicMed Daniluk, Nowak Spółka Jawna</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Reumatologiczne Indywidualna Specjalistyczna Praktyka Lekarska lek. Barbara Bazela</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCBK Iwona Czajkowska Anna Podrażka- Szczepaniak S.C.</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Clinic</name>
      <address>
        <city>Katowice</city>
        <zip>40-060</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silmedic sp. z o.o</name>
      <address>
        <city>Katowice</city>
        <zip>40-282</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GLOBE CLINICAL RESEARCH (Globe Badania Kliniczne Sp z o.o.)</name>
      <address>
        <city>Klodzko</city>
        <zip>57-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska Maciej Zymla</name>
      <address>
        <city>Knurow</city>
        <zip>44-190</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Medyczne s.c.</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grazyna Pulka Specjalistyczny Osrodek &quot;ALL-MED&quot;</name>
      <address>
        <city>Krakow</city>
        <zip>31-024</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych S.C.</name>
      <address>
        <city>Poznan</city>
        <zip>60-773</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RCMed</name>
      <address>
        <city>Sochaczew</city>
        <zip>96-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne AMED</name>
      <address>
        <city>Warsaw</city>
        <zip>03-291</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medycyna Kliniczna</name>
      <address>
        <city>Warszawa</city>
        <zip>00-660</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheuma Medicus Zaklad Opieki Zdrowotnej</name>
      <address>
        <city>Warszawa</city>
        <zip>02-118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reum-Medica S.C Eliza Roszkowska</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-244</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Emergency Medical Care</name>
      <address>
        <city>St. Petersburg</city>
        <state>Saint Petersburg</state>
        <zip>192242</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;Centre of Medical Common Practice&quot;</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultramed</name>
      <address>
        <city>Omsk</city>
        <zip>644024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPb SBIH &quot;Clinical Rheumatological Hospital # 25&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Medical Sanitary Unit#157</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIH &quot;Departmental Hospital on Station Smolensk of OJSC &quot;Russian Railways&quot;</name>
      <address>
        <city>Smolensk</city>
        <zip>214025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SAIH of Yaroslavl region &quot;Clinical Hospital of Emergency Medical Care n.a. N. V. Solovyev&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI of Yaroslavl Region &quot;Clinical Hospital # 8&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology_Site 1</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Bezanijska kosa</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Treatment and Rehabilitation &quot;Niska Banja&quot;</name>
      <address>
        <city>Niska Banja</city>
        <zip>18205</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital &quot;Dr Laza K. Lazarevic&quot; Sabac</name>
      <address>
        <city>Sabac</city>
        <zip>15000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Clinical Research</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinresco Centres (Pty) Ltd</name>
      <address>
        <city>Kempton Park</city>
        <state>Gauteng</state>
        <zip>1619</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emmed Research</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pretoria Clinical Research Unit</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naidoo, A</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4319</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinical Research Trial Unit</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winelands Medical Research Centre</name>
      <address>
        <city>Stellenbosch</city>
        <state>Western Cape</state>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional CH Dep of Rheumatology SHEI Ivano-Frankivsk NMU</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Institution of Healthcare Kharkiv City Clinical Hospital #8</name>
      <address>
        <city>Kharkiv</city>
        <zip>61176</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Medical Clinic Blagomed LLC</name>
      <address>
        <city>Kyiv</city>
        <zip>01601</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Center 'Ok!Clinic+' of International Institute of Clinical Trials LLC</name>
      <address>
        <city>Kyiv</city>
        <zip>02091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of Revmotsentr LLC</name>
      <address>
        <city>Kyiv</city>
        <zip>04070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI D.F.Chebotariov Institute of Gerontology of NAMSU</name>
      <address>
        <city>Kyiv</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH of State Border Service of Ukraine (Military Base 2522) Dept of Therapy, D.Halytskyi Lviv NMU</name>
      <address>
        <city>Lviv</city>
        <zip>79049</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.V. Sklifosovskyi Poltava RCH Dept of Rheumatology HSEIU UMSA</name>
      <address>
        <city>Poltava</city>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.Novak Transcarpathian Regional Clinical Hospital</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Pirogov Memorial Medical University</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI City Hospital #1</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69104</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI Zaporizhzhia Regional Clinical Hospital of ZRC</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI Zaporizhzhia Regional Clinical Hospital of ZRC</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200527-0060</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 25, 2017</study_first_submitted>
  <study_first_submitted_qc>July 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2017</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>American College of Rheumatology</keyword>
  <keyword>High-sensitivity C-reactive protein</keyword>
  <keyword>Bruton's tyrosine kinase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

